New combo therapy tested for Tough-to-Treat breast cancer
Disease control
Completed
This early-stage study tested the safety of combining two drugs, ARV-471 and everolimus, for people with advanced breast cancer that has stopped responding to standard hormone therapies. It involved 32 participants to find the safest and most effective dose for future research. T…
Phase: PHASE1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC